Sotera Health Company (SHC) Stock

Understand Sotera Health Company: how it makes money

Sotera Health runs sterilization plants (gamma, electron beam, ethylene oxide) and a clinical lab testing business, selling processing capacity to medical device, pharma, and food companies. About two-thirds of revenue comes from Sterigenics sterilization, while Nelson Labs testing and Nordion brachytherapy fuel supply the rest.

Each sterilization plant is a capital-intensive toll: customers pay per unit processed, and the heavy regulatory and infrastructure cost of building irradiation facilities (2026 capex of $200M to $225M) means growth is gated by execution, not demand.

Business quality (Solid): Solid: 55% gross margin, 24% operating margin, and 25% ROE on a $300M quarterly revenue base, supported by regulated multi-plant sterilization contracts.

Valuation: At 34× earnings, SHC trades 34% above the Healthcare Services average (25×).

Bull case

• Diversified sticky demand base: Sterigenics serves more than 2,000 customers, and a meaningful client is shifting North American EO sterilization capacity to Sotera, pushing revenue concentration further down and deepening the installed base.
• X-ray ramp adds growth lever: New X-ray capacity is already generating revenue and is expected to support second-half growth, adding a sterilization channel beyond the existing gamma and EO plants without requiring a new nuclear license.
• Pricing power in regulated capacity: Gross margin of 55% and operating margin of 24% reflect the difficulty of replicating irradiation infrastructure; customers face limited alternatives, allowing Sotera to maintain disciplined pricing even as capex outlays rise.

Bear case

• Capex consumes most of cash flow: 2026 capital expenditures are elevated at $200M to $225M against roughly $1.2B annualized revenue, meaning the company is spending heavily to replace and expand capacity while near-term free cash flow stays under pressure.
• Nelson Labs margin squeeze: Nelson Labs faces labor and materials inflation while its net revenue is essentially flat (minus 0.2% YoY), threatening the segment's contribution to the 24% operating margin the group relies on.
• Priced for continued outperformance: At 34.1x trailing earnings versus the Healthcare Services industry average of 25x (34% above), the stock already embeds sustained mid-single-digit growth and leaves little cushion if Nordion timing issues or litigation distract execution.

Related Companies (Healthcare Services; 8 comparable companies)

• Progyny, Inc. (PGNY)
• Viemed Healthcare, Inc. (VMD)
• Park Dental Partners, Inc. Common Stock (PARK)
• Agilon Health, Inc. (AGL)
• Addus HomeCare Corporation (ADUS)
• LifeStance Health Group, Inc. (LFST)
• The Pennant Group, Inc. (PNTG)
• P3 Health Partners Inc. (PIII)